Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group.
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Degos F, et al. Among authors: naveau s. J Hepatol. 1998 Aug;29(2):224-32. doi: 10.1016/s0168-8278(98)80007-x. J Hepatol. 1998. PMID: 9722203 Clinical Trial.
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group. Poynard T, et al. Among authors: naveau s. J Viral Hepat. 2003 May;10(3):197-204. doi: 10.1046/j.1365-2893.2003.00427.x. J Viral Hepat. 2003. PMID: 12753338 Clinical Trial.
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ, Roulot D, Naveau S, Grange JD, Poupon RE, Poupon R, Serfaty L. Fartoux L, et al. Among authors: naveau s. Clin Gastroenterol Hepatol. 2007 Apr;5(4):502-7. doi: 10.1016/j.cgh.2006.10.016. Epub 2007 Jan 29. Clin Gastroenterol Hepatol. 2007. PMID: 17261383 Clinical Trial.
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.
Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-Thoraval F, Gordien E; Deltavir study group. Roulot D, et al. J Hepatol. 2020 Nov;73(5):1046-1062. doi: 10.1016/j.jhep.2020.06.038. Epub 2020 Jul 4. J Hepatol. 2020. PMID: 32634548 Free article.
Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group.
Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois B, Samuel D, Cherqui D, Pageaux G, Bernard PH, Calmus Y, Zarski JP, Miguet JP, Chaput JC. Poynard T, et al. Among authors: naveau s. J Hepatol. 1999 Jun;30(6):1130-7. doi: 10.1016/s0168-8278(99)80269-4. J Hepatol. 1999. PMID: 10406193 Clinical Trial.
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T. Thabut D, et al. Among authors: naveau s. J Hepatol. 2006 Jun;44(6):1175-85. doi: 10.1016/j.jhep.2006.02.010. Epub 2006 Mar 13. J Hepatol. 2006. PMID: 16580087
199 results